BIOLASE Announces Upgrade of Its Market-Leading WaterLase iPlus 2.0 Dental Laser to Treat Peri-implantitis

Download as PDF

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today an upgrade of its WaterLase iPlus® 2.0 dental laser to provide dental practitioners a clinical protocol and application to assist in the effective management of peri-implantitis. A growing problem in dentistry, peri-implantitis is a destructive inflammatory process affecting the soft and hard tissues surrounding dental implants.

BIOLASE first introduced its REPAIR™ protocol for periodontitis in 2014, and has now leveraged that significant clinical accomplishment to develop the REPAIR Implant™ protocol to assist in the management of peri-implantitis. Both of these periodontal clinical protocols are now integrated into the WaterLase iPlus 2.0. WaterLase utilizes proprietary and patented Radial Firing Perio Tips™ which emit a corona of laser energy to manage infection, necrosed tissue, anaerobes and other material compromising the implant surface and surrounding periodontal structures.

“Peri-implantitis is a growing problem in implant dentistry,” said President and CEO Harold C. Flynn, Jr. “BIOLASE is committed to providing dental professionals with clinically advanced technology to address today’s dental health challenges. The REPAIR Implant protocol is an important new WaterLase capability, and we’re excited to bring it to practitioners and their patients.”

“This clinically important new addition to WaterLase is part of our continued commitment to provide better care for patients and provide a foundation for practice growth,” Flynn added.

With an increase in the number of dental implants placed around the world, incidences of peri-implantitis are a growing health issue that is frequently encountered in the dental practice. Estimates for the incidence of peri-implantitis vary between 10 and 43 percent of all dental implants placed. WaterLase technology offers a minimally invasive alternative to traditional treatment of peri-implantitis.

With the addition of the new REPAIR Implant™ protocol, the WaterLase iPlus 2.0 now provides pre-programmed settings and step-by-step applications for more than 50 procedures and clinical indications.

Advantages of the new WaterLase iPlus 2.0 REPAIR Implant protocol include:

  • Minimally invasive protocol to assist in the management of peri-mucositis and peri-implantitis
  • Easy access and not harmful to implant surface
  • Closed flap protocol can be used for early peri-implantitis
  • Treat site-specific or whole-mouth cases
  • Laser photoacoustic properties effectively debride the implant surface
  • Supported by over 40 examples of clinical evidence

To learn more about WaterLase iPlus 2.0 and the REPAIR Implant protocol visit www.biolase.com.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both the dentist and their patients. The Company's proprietary laser products incorporate approximately 250 patented and 100 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 27,600 laser systems. Laser products under development address the Company's core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, and YouTube at www.youtube.com/biolasevideos.

BIOLASE and WaterLase are trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, our strategic initiatives, the closing of the private placement and expected use of proceeds and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

BIOLASE
Louis Beltran
Product Manager and Market Intelligence Manager
949-226-8116
lbeltran@biolase.com
or
DresnerAllenCaron
Rene Caron (Investors)
rcaron@dresnerallencaron.com
or
Len Hall (Media)
lhall@dresnerallencaron.com
949-474-4300

Source: BIOLASE, Inc.

Released November 2, 2015